CGCNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends March 31
Canopy Growth Corp
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.72+0.00 (+0.38%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2016 to 2026
Gross margin
24.5%+12.2 pts over 5 years
Operating margin
-56.8%+170.7 pts over 5 years
Net margin
-92.4%+226.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.8% | -5.1% | -12.2% | – | |
| Gross profit | -12.4% | – | +0.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | -41.7% | -44.7% | |
| Return on assets | – | -25.5% | -25.8% | |
| Current ratio | 10.12 | 9.98 | 3.34 | |
| Debt to equity | 0.02 | 0.45 | 0.33 | |
| Net debt to EBITDA | 11.41× | – | – | |
| Interest coverage | – | -147.0× | -4.2× | |
| Inventory turnover | – | 1.3× | 2.1× | |
| Capex to revenue | 73.7% | 30.1% | 1.9% | |
| Diluted shares | 12M | 37M | 298M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Canopy Growth generated C$1.61B from operations and spent C$65.39M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
C$1.61B
Used
C$65.39M
Capital expenditureC$65.39M100%DividendsC$00%Share buybacksC$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-92.4%
×Asset turnover0.28×
×Equity multiplier1.73×
=Return on equity, FY2026-44.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -92.4% | 0.28× | 1.73× | -44.7% |
| FY2025 | -189.2% | 0.24× | 2.52× | -115.8% |
| FY2024 | -233.4% | 0.16× | 3.23× | -119.7% |
| FY2023 | -983.7% | 0.08× | 1.85× | -151.0% |
| FY2022 | -65.2% | 0.08× | 1.76× | -8.8% |
| FY2021 | -319.2% | 0.08× | 1.63× | -41.7% |
| FY2020 | -331.3% | 0.05× | 1.32× | -22.7% |
| FY2019 | -325.3% | 0.05× | 1.26× | -18.5% |
| FY2018 | -86.3% | 0.07× | 1.19× | -7.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
5of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-C$262.91M
- Cash generatingOperating cash flow above zero-C$63.81M
- Return on assets improvedROA up on the prior year-39.1% → -28.6%
- Earnings backed by cashOperating cash flow above net income-C$63.81M vs -C$262.91M
- Less leverageLong-term debt to assets fell32.7% → 19.4%
- Better liquidityCurrent ratio rose2.86 → 3.34
- No dilutionShare count did not rise108M → 298M
- Gross margin improvedGross margin up on the prior year29.56% → 24.48%
- More efficientAsset turnover rose0.21 → 0.31